Health Care/Hospital

Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland

* Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters * Marks Samsung Biologics' geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support * Plans further investments to add capabilities and strengthe...

2026-03-31 22:00 4876

Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2

BEIJING and BRIDGEWATER, N.J., March 31, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (SSE: 603087) today announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, evaluating investigative once-weekly insulin GZR4 Injection, have successfully met their pre-specified primary endpo...

2026-03-31 21:50 4007

NUH LAUNCHES INNOVATION HUB TO ACCELERATE SMART SOLUTIONS AND TRANSFORM HEALTHCARE DELIVERY

By driving a robust culture of innovation, the hub will provide a collaborative space to test and scale solutions with partners, speeding progress in patient care and operations SINGAPORE, March 31, 2026 /PRNewswire/ -- The National University Hospital (NUH) has launched the NUH Innovation Hub, ...

2026-03-31 21:31 3791

BON Unveils Strategic Partnership with Tigerbone Group to Launch New Natural Health Initiatives

XI'AN, China, March 31, 2026 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading provider of bio-ingredient solutions in the natural, health, and personal care industries, announced today that on February 4, 2026 it entered into a Cooperation Framework Agree...

2026-03-31 21:00 4210

Co-PSMA data published in the European Urology journal

SYDNEY, March 31, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the results fro...

2026-03-31 20:58 3903

Inaugural Rabies in Asia Conference to Be Held in Kuching

KUCHING, Malaysia, March 31, 2026 /PRNewswire/ -- Place Borneo Sdn Bhd, in collaboration with the Department of Veterinary Services Sarawak (DVSS), will host the 1st Rabies in Asia (RIA) 2026 in conjunction with the 5th Rabies in Borneo (RIB) 2026, taking place 29 September to 1 October 2026 at t...

2026-03-31 20:31 3600

LabConnect Launches SampleGISTICS® 2.0 to Digitize Clinical Trial Sample Capture

Smartphone-based solution streamlines site workflows and enables real-time visibility at the sample level RALEIGH, N.C., March 31, 2026 /PRNewswire/ -- LabConnect

2026-03-31 20:15 2374

3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone

SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc. (01530.HK ) today released its 2025 annual results announcement. Fueled by the dual core engines of breakthroughs in innovative R&D and strategic global collaboration, the company delivered a high-quality performance with bot...

2026-03-31 20:13 6516

PolyU launches accredited MSc in Dietetics programme to train next generation of nutrition leaders

HONG KONG, March 31, 2026 /PRNewswire/ -- In a significant move to address the growing demand for highly qualified healthcare professionals, The Hong Kong Polytechnic University (PolyU) has officially launched Master of Science in Dietetics programme since 2025. The programme is designed to bridg...

2026-03-31 18:38 1905

Diagens Biotechnology Raises US$101 Million in Hong Kong IPO; Shares More Than Double on First Day of Trading

Public offering oversubscribed 1,073 times as medical imaging AI company debuts on HKEX HANGZHOU, China, March 31, 2026 /PRNewswire/ -- Hangzhou Diagens Biotechnology Co., Ltd. (HKEX: 02526) today began trading on the Main Board of The Stock Exchange of Hong Kong. Shares closed at HK$202.60, up ...

2026-03-31 18:34 5357

Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026

HONG KONG, March 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK)  ("Akeso" or the "Company") announced the results of health-related quality of life (HRQoL) data (Poster: 107P) from the HARMONi-2 study at the 2026 European Lung Cancer Congress (ELCC). The study evaluated ivonescimab, the company's...

2026-03-31 17:40 3922

Guo Guangchang: Fosun International's NAV reaches HKD18.1 Per Share, Focusing Resources on Core, High‑Growth Areas

HONG KONG, March 31, 2026 /PRNewswire/ -- On the morning of 31 March, Guo Guangchang, Chairman of Fosun International, stated at Fosun International's 2025 annual results presentation that the RMB23.4 billion impairment provision was a "prudent accounting measure, not a reflection of operational ...

2026-03-31 17:36 6168

SirPAD: Primary Results confirm the safety and efficacy of Sirolimus Coated Balloon in PAD

TAMPA, Fla., March 31, 2026 /PRNewswire/ -- Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the presentation of the world's largest randomised controlled trial of a Sirolimus-coa...

2026-03-31 16:27 3701

DNV SELECTED TO CERTIFY CLASS D DEVICES FOR LEADING U.S. MANUFACTURER UNDER EU IVDR

DNV supports the manufacturer's transition to new regulation with its digital certification platform and transparent, predictable project management. OSLO, Norway, March 31, 2026 /PRNewswire/ -- DNV, a designated Notified Body for the European Union's In Vitro Diagnostic Regulation (IVDR) and Med...

2026-03-31 15:00 4384

Abbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children

SHANGHAI, March 31, 2026 /PRNewswire/ -- On 30 March, 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced thatthe U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for ABSK061, a highly selective small-...

2026-03-31 14:10 3970

Amorepacific, Viol Medical Sign MOU on Beauty and Medical Devices

SEOUL, South Korea, March 31, 2026 /PRNewswire/ -- Amorepacific announced on March 27 that it has signed a memorandum of understanding (MOU) with Viol Medical, an energy‑based medical device company, to collaborate in the beauty and medical device sectors. The collaboration aligns with Amorepacif...

2026-03-31 13:00 4042

AIA launches ProsperLife Insurance Plan: Lifelong protection for every stage of life

Premiums from only HKD 60 per day for an HKD 1.9 million sum assured HONG KONG, March 31, 2026 /PRNewswire/ -- AIA Hong Kong & Macau announces the launch of the ProsperLife Insurance Plan, a participating whole life insurance plan designed to support customers and their families' life protection ...

2026-03-31 12:40 3037

NAVER D2SF Makes Follow-On Investment in Soundable Health, an AI-Driven Health Tech Startup Scaling in the U.S. Market

SEOUL, South Korea, March 30, 2026 /PRNewswire/ -- NAVER D2SF, the corporate venture capital arm of NAVER, has made a follow-on investment in Soundable Health, a health tech startup leveraging AI-powered acoustic analysis to enable clinical-grade diagnostics through everyday devices. Having parti...

2026-03-31 08:30 4609

NAVER D2SF Makes Follow-On Investment in Nuvilab, AI Nutrition Analytics Startup

SEONGNAM, South Korea, March 30, 2026 /PRNewswire/ -- NAVER D2SF, the corporate venture capital arm of NAVER, has made a follow-on investment in Nuvilab, an AI-powered nutrition analytics healthcare startup. Following its seed investment shortly after the company's founding in 2021, NAVER D2SF ha...

2026-03-31 08:30 4060

Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema

* OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab * New anatomic data demonstrates OLN324 achieves faster, greater, and more durable re...

2026-03-31 08:00 4534
1 ... 27282930313233 ... 859